These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

242 related items for PubMed ID: 18639330

  • 1. Prognostic implication of endometriosis in clear cell carcinoma of the ovary.
    Orezzoli JP, Russell AH, Oliva E, Del Carmen MG, Eichhorn J, Fuller AF.
    Gynecol Oncol; 2008 Sep; 110(3):336-44. PubMed ID: 18639330
    [Abstract] [Full Text] [Related]

  • 2. Survival impact of capsule rupture in stage I clear cell carcinoma of the ovary in comparison with other histological types.
    Higashi M, Kajiyama H, Shibata K, Mizuno M, Mizuno K, Hosono S, Kawai M, Nakanishi T, Nagasaka T, Kikkawa F.
    Gynecol Oncol; 2011 Dec; 123(3):474-8. PubMed ID: 21955484
    [Abstract] [Full Text] [Related]

  • 3. Cystic and adenofibromatous clear cell carcinomas of the ovary: distinctive tumors that differ in their pathogenesis and behavior: a clinicopathologic analysis of 122 cases.
    Veras E, Mao TL, Ayhan A, Ueda S, Lai H, Hayran M, Shih IeM, Kurman RJ.
    Am J Surg Pathol; 2009 Jun; 33(6):844-53. PubMed ID: 19342944
    [Abstract] [Full Text] [Related]

  • 4. For women receiving chemotherapy for clinically apparent early ovarian cancer, is there a benefit to surgical staging?
    Dizon DS, Restivo A, Lomme M, Charbonneau N, Brard L, Hughes T, Weitzen S, Legare R, Granai CO, Disilvestro P.
    Am J Clin Oncol; 2008 Feb; 31(1):39-42. PubMed ID: 18376226
    [Abstract] [Full Text] [Related]

  • 5. Stage IVB endometrial cancer: does applying an ovarian cancer treatment paradigm result in similar outcomes? A case-control analysis.
    Landrum LM, Moore KN, Myers TK, Lanneau GS, McMeekin DS, Walker JL, Gold MA.
    Gynecol Oncol; 2009 Feb; 112(2):337-41. PubMed ID: 19041126
    [Abstract] [Full Text] [Related]

  • 6. Prognostic factors for high-risk early-stage epithelial ovarian cancer: a Gynecologic Oncology Group study.
    Chan JK, Tian C, Monk BJ, Herzog T, Kapp DS, Bell J, Young RC, Gynecologic Oncology Group.
    Cancer; 2008 May 15; 112(10):2202-10. PubMed ID: 18348296
    [Abstract] [Full Text] [Related]

  • 7. When 'never-events' occur despite adherence to clinical guidelines: the case of venous thromboembolism in clear cell cancer of the ovary compared with other epithelial histologic subtypes.
    Duska LR, Garrett L, Henretta M, Ferriss JS, Lee L, Horowitz N.
    Gynecol Oncol; 2010 Mar 15; 116(3):374-7. PubMed ID: 19922988
    [Abstract] [Full Text] [Related]

  • 8. Survival impact of adjuvant paclitaxel and carboplatin for early-stage ovarian clear-cell carcinoma with complete surgical staging.
    Kajiyama H, Shibata K, Suzuki S, Ino K, Kawai M, Nagasaka T, Nawa A, Kikkawa F.
    Gynecol Obstet Invest; 2011 Mar 15; 72(4):252-6. PubMed ID: 22041903
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Endometrioid adenocarcinoma of the ovary and its relationship to endometriosis.
    McMeekin DS, Burger RA, Manetta A, DiSaia P, Berman ML.
    Gynecol Oncol; 1995 Oct 15; 59(1):81-6. PubMed ID: 7557621
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Clinical characteristics of clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy.
    Sugiyama T, Kamura T, Kigawa J, Terakawa N, Kikuchi Y, Kita T, Suzuki M, Sato I, Taguchi K.
    Cancer; 2000 Jun 01; 88(11):2584-9. PubMed ID: 10861437
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. [Clinical features and drug resistance characteristics of ovarian clear cell adenocarcinoma and analysis of its prognostic factors].
    Zhang CY, Guo HY, Li H, Wen HW, Liang XD, Qiao J.
    Zhonghua Zhong Liu Za Zhi; 2012 Sep 01; 34(9):688-91. PubMed ID: 23159083
    [Abstract] [Full Text] [Related]

  • 15. Prognostic determinants in patients with uterine and ovarian clear carcinoma.
    Rauh-Hain JA, Winograd D, Growdon WB, Schorge JO, Goodman AK, Boruta DM, Berkowitz RS, Horowitz NS, Del Carmen MG.
    Gynecol Oncol; 2012 May 01; 125(2):376-80. PubMed ID: 22366593
    [Abstract] [Full Text] [Related]

  • 16. Comparison of clinical outcomes of patients with clear cell and endometrioid ovarian cancer associated with endometriosis to papillary serous carcinoma of the ovary.
    Davis M, Rauh-Hain JA, Andrade C, Boruta DM, Schorge JO, Horowitz NS, May T, del Carmen MG.
    Gynecol Oncol; 2014 Mar 01; 132(3):760-6. PubMed ID: 24440832
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Nondysgerminomatous ovarian tumors: clinical characteristics, treatment, and outcome. A case-controlled study.
    Ghaemmaghami F, Hasanzadeh M, Karimi Zarchi M, Fallahi A.
    Int J Surg; 2008 Oct 01; 6(5):382-6. PubMed ID: 18715834
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.